Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients

Руженцова, Т. А.; Хавкина, Д. А.; Чухляев, Павел; Гарбузов, Александр; Плоскирева, А.А.

doi:10.36233/0507-4088-14

Cited by 5 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В то же время приём новых оральных антикоагулян-тов (НОАК) ривароксабана, апиксабана, дабигатрана снижает вероятность тяжёлого течения и неблагоприятных исходов при развитии коронавирусной инфекции. Число госпитализаций было достоверно меньше в группе пациентов, получавших НОАК, 19 % против 66 % в контрольной группе, где не назначали никаких препаратов, влияющих на свёртываемость крови [46]. Среди амбулаторных пациентов с COVID-19 с кардиометаболическими заболеваниями предшествующее применение терапии НОАК по сравнению с терапией антагонистами витамина К на момент постановки диагноза COVID-19 продемонстрировало более низкий риск артериальных или венозных тромботических осложнений без увеличения риска кровотечения [47].…”

Section: компьютерная томография (ктunclassified

Factors associated with adverse outcome among hospitalized patients with moderate to severe COVID-19

Mishinova

Gomon

Kolbin

et al. 2023

GCP

View full text Add to dashboard Cite

Aims. To consider factors associated with adverse outcome among hospitalized patients with moderate and severe COVID-19.Materials and methods. Data from 345 case histories of adult patients hospitalized with moderate to severe COVID-19 were analyzed in a single-center retrospective study. Characteristics by sex, age, number of days from disease onset to admission to hospital, duration of hospitalization, duration of disease, population characteristics by medical history of comorbidities and self-medication, outcome of hospitalization and medical technologies used in hospital conditions were given for the whole cohort of patients. All parameters were analyzed using descriptive statistics methods. Qualitative variables are given in absolute (n) and relative (%) values with 95% confidence interval. Continuous variables were presented as median and quartiles. Risk factors for mortality were determined across groups using the χ2 criterion and odds ratio.Results. There was no demonstrated effect of gender, degree of pulmonary tissue lesions on computed tomography data, or time of initiation of respiratory support on disease outcome. At the same time, the age older than 65 years as well as neoplasms, type 2 diabetes mellitus, dementia, Stage 3 arterial hypertension, chronic heart failure, coronary heart disease, myocardial infarction and stroke history, chronic obstructive pulmonary disease, bronchiectatic disease, urogenital diseases were the predictors of unfavorable outcome in patients with moderate and severe COVID-19 form. Prehospital use of antiplatelet agents, direct and indirect oral anticoagulants, drugs affecting the renin-angiotensin system, systemic glucocorticosteroids, antibiotics, antiviral drugs, and analgesics was associated with a decrease in the mortality rate in patients with moderate-to-severe COVID-19, as well as timely use of pronposition and transfer to intensive care unit.Conclusions. Our findings are partially consistent with previous reports on the effect of risk factors on COVID-19 outcomes.

show abstract

Section: компьютерная томография (ктunclassified

Factors associated with adverse outcome among hospitalized patients with moderate to severe COVID-19

Mishinova

Gomon

Kolbin

et al. 2023

GCP

View full text Add to dashboard Cite

show abstract

“…Эти показатели способны отразить степень клеточного повреждения миокарда (тропонин-I и МВ-КК), прогрессирование сердечной недостаточности (NТ-рroBNP) и тромбообразование (Д-димер). С приходом пандемии новой коронавирусной инфекции (СOVID-19) наиболее остро выявилась необходимость определения и коррекции этих нарушений, однако остро встал вопрос о том, какие именно из перечисленных маркеров при СOVID-19 покажут большую результативность [1][2][3][4][5][6][7].…”

Section: Relationships Andunclassified

Laboratory features of cardiovascular injury in COVID-19 and other acute respiratory viral infections

2021

Self Cite

View full text Add to dashboard Cite

The article presents data from a study of specific cardiac markers in patients with acute respiratory viral infection (ARVI) or coronavirus disease 2019 (COVID-19). COVID-19 caused by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) is characterized by cardiovascular injury. However, with other ARVIs, the prevalence of heart involvement is also high and, according to the literature data, is about 20%. At the same time, laboratory characteristics of these lesions have significant differences in ARVI and COVID-19, which necessitates different approaches to therapy.Aim. To determine the most significant markers for the diagnosis of cardiovascular involvement in patients with COVID-19.Material and methods. A total of 60 patients were included in the study: main group (n=30), COVID-19 was laboratory confirmed; comparison group (n=30), other ARVI pathogens were verified. The groups were completely comparable in sex, age and severity of disease course. The average values of troponin, creatine kinase MB, N-terminal pro-brain natriuretic peptide (NT-proBNP) and D-dimer were compared in patients of both groups in the acute disease phase, corresponding from 1 to 8 days from the symptoms’ onset. Data analysis was performed using a two-sided independent samples t-test using SPSS Statistics version 23.Results. The higher levels of troponin-I and D-dimer were significantly more common in the main group. The mean value of creatine kinase MB did not exceed the upper limits of reference values. There were no significant differences in NTproBnP levels between the groups. At the same time, in both groups, its level significantly exceeded the age reference values.Conclusion. The most effective markers of cardiovascular complications in COVID-19 patients should be considered troponin-I, D-dimer and NT-proBNP. Early diagnosis and laboratory monitoring in dynamics is important for the timely detection of cardiac pathology and alteration of therapy regimen.

show abstract

Issues of etiotropic therapy in conditions of ‘omicron’ strain of SARS-CoV‑2 spreading: Real practice

Чухляев

Хавкина

Janibekov³

et al. 2022

Medicinskij alfavit

View full text Add to dashboard Cite

The article presents clinical examples of treatment of patients with COVID-19 diagnosed during the period of active spread of the ‘omicron’ strain. The results of symptomatic therapy and the need for the appointment of etiotropic drugs, including in the late stages of the disease, are considered, which raises the greatest number of questions in clinical practice. In the presented examples, patients received medicines approved by the current temporary guidelines for the diagnosis, treatment and prevention of COVID-19 of the Ministry of Health of the Russian Federation. The analysis of the course of the disease confirms the continuing need for the appointment of etiotropic therapy in the conditions of the spread of the ‘omicron’ variant, including in the second week of the disease. Umifenovir therapy as part of a comprehensive treatment regimen suspends the progression of COVID-19 and leads to relief of symptoms. Symptomatic treatment in the conditions of the spread of a new variant of the coronavirus omicron cannot replace etiotropic and pathogenetic therapy.

show abstract

Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients

Cited by 5 publications

References 6 publications

Factors associated with adverse outcome among hospitalized patients with moderate to severe COVID-19

Factors associated with adverse outcome among hospitalized patients with moderate to severe COVID-19

Laboratory features of cardiovascular injury in COVID-19 and other acute respiratory viral infections

Issues of etiotropic therapy in conditions of ‘omicron’ strain of SARS-CoV‑2 spreading: Real practice

Contact Info

Product

Resources

About